Welcome to our dedicated page for BULLFROG AI HLDGS news (Ticker: BFRG), a resource for investors and traders seeking the latest updates and insights on BULLFROG AI HLDGS stock.
BullFrog AI Holdings Inc. (NASDAQ: BFRG) is a biotechnology innovator using artificial intelligence to accelerate drug discovery and clinical development. This news hub provides investors and industry professionals with timely updates on the company's AI-driven research initiatives, strategic partnerships, and therapeutic advancements.
Access consolidated information on BFRG's latest press releases including clinical trial progress, regulatory milestones, and technology developments related to its proprietary bfLEAP platform. Our curated collection serves as an essential resource for tracking advancements in precision medicine and AI-powered pharmaceutical research.
Key updates cover therapeutic focus areas such as liver disease treatments, obesity research, and neuropsychiatric disorder solutions. Stay informed about collaborative projects with leading research institutions and data-driven breakthroughs in biomarker discovery.
Bookmark this page for direct access to BullFrog AI's official announcements and third-party analysis. Regularly updated content ensures you maintain current awareness of the company's position at the intersection of biotechnology and artificial intelligence innovation.
Rhea-AI Summary
BullFrog AI Holdings, Inc. announces the Underwriter's decision to exercise their over-allotment option to purchase 218,382 shares of the Company's common stock. The offering was made via a prospectus filed with the SEC and facilitated by WallachBeth Capital, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
-
Rhea-AI Summary
BullFrog AI Holdings, Inc. announces a fireside chat with CEO Vin Singh and Dr. Daniel R. Weinberger to discuss groundbreaking collaboration with LIBD on psychiatric research using AI and machine learning. The partnership aims to provide new insights into brain disorders and potential treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.15%
Tags
-
Rhea-AI Summary
WallachBeth Capital LLC announced that BullFrog AI Holdings, Inc. has completed an underwritten public offering, raising approximately $5.7 million. The company offered 1,507,139 shares of common stock at a public offering price of $3.782 per share. Additionally, the underwriters have a 45-day option to purchase an additional 226,071 shares to cover over-allotments. The offering was managed by WallachBeth Capital, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.64%
Tags
Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ:BFRG) has closed an underwritten public offering, raising approximately $5,700,000 in gross proceeds. The company intends to use the net proceeds for working capital and general corporate purposes. WallachBeth Capital, LLC acted as the sole book-running manager for the offering. The offering was made in accordance with a registration statement on Form S-1 (File No. 333-276740) filed with the SEC and became effective on January 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.64%
Tags
-
Rhea-AI Summary
WallachBeth Capital LLC announced that BullFrog AI Holdings, Inc. priced an underwritten public offering of 1,507,139 shares of common stock and accompanying warrants, with gross proceeds of approximately $5,700,000. The offering is expected to close on February 5, 2024, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.34%
Tags
-
Rhea-AI Summary
BullFrog AI Holdings, Inc. announced the pricing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share, resulting in gross proceeds of approximately $5,700,000. The company also granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock and/or warrants to cover over-allotments. The net proceeds from the offering will be used for working capital and other general corporate purposes. The offering is expected to close on February 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.34%
Tags
Rhea-AI Summary
BullFrog AI Holdings, Inc. announces the appointment of two distinguished scientific advisors to its advisory board, Dr. Gwenn S. Smith and Dr. Jeremiah Wala. Dr. Smith brings expertise in brain imaging and neuropsychiatry, while Dr. Wala adds clinical insight and computational expertise to the company's scientific advisory board. Both advisors are expected to contribute to the company's mission of developing breakthrough therapies and improving patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
-
Rhea-AI Summary
BullFrog AI Holdings, Inc. announced early results from its collaboration with the Lieber Institute for Brain Development that could revolutionize the understanding and treatment of psychiatric disorders. The collaboration has successfully stratified brain expression data, offering unprecedented insights into psychiatric conditions. The proprietary data from LIBD included gene expression data from over 2,800 brain samples encompassing schizophrenia, bipolar disorder, major depressive disorder, and non-psychiatric control brains. Utilizing graph analytics, BullFrog AI and LIBD have, for the first time, clustered subjects based solely on their biological data, independent of their behavioral diagnoses. This innovative approach has yielded promising insights, highlighting distinct differences and similarities in biological pathways across various brain disorders. The market opportunity for new treatments in psychiatric disorders is vast and underserved, presenting a potential paradigm shift in treatment approaches.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.83%
Tags
-
Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) has announced that the Australian Patent Office has issued Patent No. 2019216757 protecting the Company’s novel prodrugs derived from mebendazole and their use in treating cancers and other diseases. This patent further strengthens the intellectual property protection of BF-223 and related compounds, including positive results from a preclinical study demonstrating that BF-223 has anticancer activity in an animal model for glioblastoma. The patented compounds exhibit improved solubility and oral bioavailability relative to the parent drug, addressing a key difficulty associated with the potential use of mebendazole for oncology indications. The company is looking forward to working with strategic partners to monetize this promising asset for the treatment of glioblastoma and other oncology indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.13%
Tags
Rhea-AI Summary
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) announces CEO's participation in Webull LIVE! Healthcare Webinar
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
BULLFROG AI HLDGS INC
Nasdaq:BFRG
BFRG Rankings
BFRG Stock Data
15.63M
6.97M
29.2%
11.72%
6.24%
Health Information Services
Pharmaceutical Preparations
United States
GAITHERSBURG